Atorvastatin: lipid lowering activity, pleiotropic properties and efficacy in prevention of atherosclerosis and coronary heart disease
Bubnova, M.G.
Kardiologiia 44(8): 96-104
2004
ISSN/ISBN: 0022-9040 PMID: 15340338 Document Number: 569757
The review presents data on pharmacological properties of atorvastatin, its lipid lowering activity, and action on main mechanisms of atherogenesis. Favorable pleiotropic effects of atorvastatin such as normalization of endothelial function, antiinflammatory, antithrombotic and antioxidant activity contribute to stabilization of atheromatous plaques. Clinical trials revealing early and significant effects of the drug on main end points have demonstrated its high value for primary and secondary prevention of atherosclerosis.
Document emailed within 1 workday
Related Documents
Wagner, M.; Goetghebeur, M.; Merikle, E.; Pandya, A.; Chu, P.; Taylor, D.C.A. 2009: Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada Canadian Journal of Clinical Pharmacology 16(2): E331-E345Santanu, G.; Suhrita, P.; Mookerjee, S.; Tania, K.; Mita, S.; Pramit, G.; Sharmila, G.; Miraj, M.; Debdutta, M. 2011: Lipid modifying action of atorvastatin in comparison to combination of atorvastatin and nicotinic acid in patients with ischaemic heart disease Indian Heart Journal 63(5): 434-437
2015: Switching from high-efficacy lipid-lowering therapies [atorvastatin or rosuvastatin] to simvastatin and the results on low-density lipoprotein cholesterol level Journal of the Medical Association of Thailand 98(1): 21-25
Zhdan, V.; Khaymenova, G.; Shilkina, L.; Martynyuk, D.; Babanina, M.; Mamontova, T. 2017: Determine the effectiveness of lipid-lowering therapy in patients with chronic obstructive pulmonary disease combined with coronary heart disease Wiadomosci Lekarskie 70(2 Part 2): 303-305
Athyros, V.G.; Mikhailidis, D.P.; Papageorgiou, A.A.; Mercouris, B.R.; Athyrou, V.V.; Symeonidis, A.N.; Basayannis, E.O.; Demitriadis, D.S.; Kontopoulos, A.G. 2002: Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study Current medical research and opinion 18(8): 499-502
Lankin, V.Z.; Gerasimova, E.N.; Kasatkina, L.V.; Tikhaze, A.K.; Suchkova, S.N. 1979: Lipid peroxides and atherosclerosis. the enzymatic detoxication of lipid peroxides in the blood in ischemic heart disease due to coronary artery arteriosclerosis Kardiologiia 19(6): 71-76
McKenna, C.J.; Sugrue, D.D. 1995: Secondary prevention in coronary heart disease. Fact: lowering cholesterol saves lives Irish Medical Journal 88(6): 191
Abdel Hay, A.; Kramer, M.; Keller, L.; Retsagi, G. 1970: The fatty acid composition of serum total lipids and lipid fractions in coronary heart disease and cerebral atherosclerosis Journal of the Egyptian Medical Association 53(5): 309-320
Heinzl, S. 1993: Coronary heart disease. New guidelines of the European Society of Atherosclerosis for prevention Medizinische Monatsschrift für Pharmazeuten 16(7): 210-213
Bespalova, I.D.; Kaliuzhin, V.V.; Riazantseva, N.V.; Mediantsev, I.A.; Osikhov, I.A.; Murashev, B.I. 2013: Pleiotropic effects of atorvastatin and dynamics of quality of life characteristics in patients with hypertensive disease and metabolic syndrome Klinicheskaia Meditsina 91(12): 46-50
Supanich, B. 1999: Aggressive lipid-lowering in stable patients with coronary artery disease Journal of Family Practice 48(10): 749-750
Muñoz, M.A.; Subirana, I.; Ramos, R.; Franzi, A.; Vila, J.; Marrugat, J. 2008: Efficacy of an intensive prevention programme of coronary heart disease: 5 year follow-up outcomes Medicina Clinica 130(14): 521-525
Teo, K.K.; Burton, J.R.; Buller, C.; Plante, S.; Yokoyama, S.; Montague, T.J. 1997: Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). SCAT Investigators Canadian Journal of Cardiology 13(6): 591-599
Martens, L.L.; Guibert, R. 1994: Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease Clinical Therapeutics 16(6): 1052-62; discussion 1036
Gao, J.; Cong, H.-l.; Mao, Y.-m.; Liu, Y.; Zhang, N.; Chen, Q.; Liu, T.; Cui, R.-z. 2013: Effects of genetic variations of cholesteryl ester transfer protein on atorvastatin treatment efficacy and clinical outcomes in patients with coronary artery disease Zhonghua Yi Xue Za Zhi 93(28): 2195-2199
Hwang, S.J.; Ballantyne, C.M.; Sharrett, A.R.; Smith, L.C.; Davis, C.E.; Gotto, A.M.; Boerwinkle, E. 1997: Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study Circulation 96(12): 4219-4225
Liping, Z.; Xiufang, L.; Tao, Y.; Baomin, Z.; Houshuai, T. 2018: Efficacy comparison of rosuvastatin and atorvastatin in the treatment of atherosclerosis and drug safety analysis Pakistan Journal of Pharmaceutical Sciences 31(5(Special): 2203-2208
Lu, G.; Xu, Z.-W.; Zhang, Y.-L.; Yang, Z.-J.; Zhang, X.-L.; Yin, K.-S. 2007: Correlation among obstructive sleep apnea syndrome, coronary atherosclerosis and coronary heart disease Chinese Medical Journal 120(18): 1632-1634
Hilb, J.A. 1983: Physical activity in the prevention of coronary atherosclerosis Journal of the Kentucky Medical Association 81(6): 351-357
Arntz, H.R.; Wunderlich, W.; Schnitzer, L.; Stern, R.; Fischer, F.; Agrawal, R.; Linderer, T.; Schultheiss, H.P. 1999: Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease. Results from the Lipid-Coronary Artery Disease (L-CAD) Study Zeitschrift für Kardiologie 88(8): 582-590